Analyst Ratings For Achillion Pharmaceuticals (NASDAQ:ACHN)
Today, B. Riley initiated coverage on Achillion Pharmaceuticals (NASDAQ:ACHN) with a Neutral with a price target of $3.50.
Some recent analyst ratings include
- 2/8/2018-B. Riley initiated coverage with a Neutral rating.
- 12/11/2017-Leerink Swann Reiterated Rating of Buy.
- 9/17/2017-Chardan Capital Reiterated Rating of Neutral.
- 9/12/2017-Robert W. Baird Reiterated Rating of Neutral.
- 4/26/2017-Jefferies Group Reiterated Rating of Hold.
Recent Insider Trading Activity For Achillion Pharmaceuticals (NASDAQ:ACHN)
Achillion Pharmaceuticals (NASDAQ:ACHN) has insider ownership of 7.24% and institutional ownership of 76.78%.
- On 11/20/2017 & Johnson Johnson, Major Shareholder, sold 18,367,346 with an average share price of $2.75 per share and the total transaction amounting to $50,510,201.50.
- On 12/22/2016 Jason S Fisherman, Director, bought 10,000 with an average share price of $3.96 per share and the total transaction amounting to $39,600.00.
- On 12/5/2016 Mary Kay Fenton, CFO, bought 2,500 with an average share price of $4.11 per share and the total transaction amounting to $10,275.00.
- On 12/2/2016 Joel C Barrish, Insider, bought 2,500 with an average share price of $4.06 per share and the total transaction amounting to $10,150.00.
- On 12/30/2015 David Apelian, insider, sold 10,000 with an average share price of $10.50 per share and the total transaction amounting to $105,000.00.
- On 12/28/2015 Mary Kay Fenton, CFO, sold 43,500 with an average share price of $10.08 per share and the total transaction amounting to $438,480.00.
- On 11/11/2015 Nicole Vitullo, Director, sold 550,000 with an average share price of $10.17 per share and the total transaction amounting to $5,593,500.00.
Recent Trading Activity for Achillion Pharmaceuticals (NASDAQ:ACHN)
Shares of Achillion Pharmaceuticals closed the previous trading session at 2.87 down -0.05 1.71% with 2.815000057220459 shares trading hands.
